AU2014230812B2 - Process for making benzoxazepin compounds - Google Patents

Process for making benzoxazepin compounds Download PDF

Info

Publication number
AU2014230812B2
AU2014230812B2 AU2014230812A AU2014230812A AU2014230812B2 AU 2014230812 B2 AU2014230812 B2 AU 2014230812B2 AU 2014230812 A AU2014230812 A AU 2014230812A AU 2014230812 A AU2014230812 A AU 2014230812A AU 2014230812 B2 AU2014230812 B2 AU 2014230812B2
Authority
AU
Australia
Prior art keywords
reacting
bromo
methyl
acid
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014230812A
Other languages
English (en)
Other versions
AU2014230812A8 (en
AU2014230812A1 (en
Inventor
Remy Angelaud
Danial R. Beaudry
Diane E. Carrera
Sushant Malhotra
Travis Remarchuk
Frederic St-Jean
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2014230812A1 publication Critical patent/AU2014230812A1/en
Publication of AU2014230812A8 publication Critical patent/AU2014230812A8/en
Application granted granted Critical
Publication of AU2014230812B2 publication Critical patent/AU2014230812B2/en
Priority to AU2016204432A priority Critical patent/AU2016204432B2/en
Priority to AU2018201393A priority patent/AU2018201393A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2014230812A 2013-03-13 2014-03-12 Process for making benzoxazepin compounds Ceased AU2014230812B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2016204432A AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
PCT/EP2014/054786 WO2014140073A1 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016204432A Division AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds

Publications (3)

Publication Number Publication Date
AU2014230812A1 AU2014230812A1 (en) 2015-09-03
AU2014230812A8 AU2014230812A8 (en) 2015-09-10
AU2014230812B2 true AU2014230812B2 (en) 2016-04-07

Family

ID=50241450

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014230812A Ceased AU2014230812B2 (en) 2013-03-13 2014-03-12 Process for making benzoxazepin compounds
AU2016204432A Ceased AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A Abandoned AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2016204432A Ceased AU2016204432B2 (en) 2013-03-13 2016-06-28 Process for making benzoxazepin compounds
AU2018201393A Abandoned AU2018201393A1 (en) 2013-03-13 2018-02-27 Process for making benzoxazepin compounds

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP3845540A1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR20180070715A (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA2948765A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2018109979A (enExample)
SG (2) SG10201706760YA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
SI3317284T1 (sl) 2015-07-02 2020-02-28 F. Hoffmann-La Roche Ag Spojine benzoksazepin oksazolidinona in načini uporabe
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
US10981877B2 (en) * 2016-07-29 2021-04-20 Japan Tobacco Inc. Production method for pyrazole-amide compound
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
PL3555107T3 (pl) 2016-12-15 2021-07-05 F. Hoffmann-La Roche Ag Sposób wytwarzania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
CA3124330A1 (en) 2018-12-21 2020-06-25 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
AU1228100A (en) * 1998-10-23 2000-05-15 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
KR20040024564A (ko) 2001-07-12 2004-03-20 아베시아 리미티드 마이크로캡슐화된 촉매, 이의 제조 방법 및 이의 사용 방법
US20050014805A1 (en) * 2001-10-12 2005-01-20 Chenzhi Zhang Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
KR101083177B1 (ko) * 2006-10-23 2011-11-11 에스지엑스 파마슈티컬스, 인코포레이티드 트리아졸로-피리다진 단백질 키나제 조정제
AU2007309149C1 (en) * 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ES2531002T3 (es) * 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
CA2701292C (en) * 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009105500A1 (en) * 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
AR071112A1 (es) 2008-03-31 2010-05-26 Genentech Inc Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen.
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
PL2483278T3 (pl) 2009-09-28 2014-05-30 Hoffmann La Roche Związki benzoksazepinowe stanowiące inhibitor pi3k i ich zastosowanie w leczeniu nowotworu
WO2011053688A1 (en) * 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
CA2825966A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Also Published As

Publication number Publication date
JP6663459B2 (ja) 2020-03-11
KR20150119033A (ko) 2015-10-23
KR101821468B1 (ko) 2018-01-23
EP3845540A1 (en) 2021-07-07
AU2016204432A1 (en) 2016-07-21
JP6363120B2 (ja) 2018-07-25
CA3005118A1 (en) 2014-09-18
SG11201507394RA (en) 2015-10-29
AU2016204432B2 (en) 2017-12-07
JP2018008959A (ja) 2018-01-18
NZ711192A (en) 2019-04-26
JP2019089762A (ja) 2019-06-13
JP2019031493A (ja) 2019-02-28
EP3404032A2 (en) 2018-11-21
IL240793A0 (en) 2015-10-29
EP3404032A3 (en) 2019-03-13
KR101871133B1 (ko) 2018-06-25
RU2649976C2 (ru) 2018-04-06
CA2897618A1 (en) 2014-09-18
SG10201706760YA (en) 2017-10-30
US9303043B2 (en) 2016-04-05
KR20170070270A (ko) 2017-06-21
KR20180070715A (ko) 2018-06-26
WO2014140073A1 (en) 2014-09-18
CA2948763A1 (en) 2014-09-18
EP2970329A1 (en) 2016-01-20
US20140275523A1 (en) 2014-09-18
JP2016512209A (ja) 2016-04-25
JP2020114814A (ja) 2020-07-30
EP3404032B1 (en) 2025-07-02
HK1215433A1 (zh) 2016-08-26
CN108929333A (zh) 2018-12-04
AU2014230812A8 (en) 2015-09-10
RU2018109979A (ru) 2019-02-28
EP3404032C0 (en) 2025-07-02
CA3005112A1 (en) 2014-09-18
MX2015011438A (es) 2016-02-03
CA3005103A1 (en) 2014-09-18
CN105377856A (zh) 2016-03-02
RU2015138488A (ru) 2017-04-20
AU2018201393A1 (en) 2018-03-15
AR095365A1 (es) 2015-10-14
CN105377856B (zh) 2018-05-22
CA2948765A1 (en) 2014-09-18
JP6442005B2 (ja) 2018-12-19
CA2948763C (en) 2018-04-24
BR112015020716A2 (pt) 2017-07-18
JP2018150298A (ja) 2018-09-27
AU2014230812A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
AU2014230812B2 (en) Process for making benzoxazepin compounds
KR20160012194A (ko) 이미다조피롤리디논 유도체 및 질환의 치료에서의 그의 용도
KR101698283B1 (ko) 티에노피리미딘 화합물의 제조 방법
IL211277A (en) Imidazolidine compounds as an androgen receptor modulator
WO2017060326A1 (en) Process for the preparation of (e)-3-(4-((e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
CA2977752A1 (en) Benzimidazole compound for preventing or treating a disease caused by abnormal prs activity, method for preparing the same and pharmaceutical composition comprising the same
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
TWI902864B (zh) 新穎二唑系選擇性hdac6抑制劑及其用途
TW202220980A (zh) 新穎二唑系選擇性hdac6抑制劑

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 29 , NO 34 , PAGE(S) 5136 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENENTECH, INC.; F. HOFFMANN-LA ROCHE AG, APPLICATION NO. 2014230812, UNDER INID (71) REMOVE CO-APPLICANT GENENTECH, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired